Short answer
SELLAS Life Sciences Group, Inc. (SLS) filed an 8-K current report with the SEC on June 25, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Enhanced retention protections for CEO, CFO and Chief Development Officer through amended severance and change-of-control agreements.
SELLAS Life Sciences Group, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Enhanced retention protections for CEO, CFO and Chief Development Officer through amended severance and change-of-control agreements
- CFO and Chief Development Officer receive nine months’ salary, pro rata target bonus and up to nine months’ COBRA outside change of control
- Change-of-control termination triggers 15 months’ salary, target bonus, up to 18 months’ COBRA and full equity-award vesting
- CEO change-of-control severance payments shifted to lump-sum settlement, with other employment terms unchanged
- Benefits contingent on executing separation and general release agreements
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SELLAS Life Sciences Group, Inc. 8-K filings
Get the next SLS 8-K as it lands
Follow SLS for push alerts, or ask the research agent what this filing means.